Patients with muscle-invasive urothelial carcinoma (MIUC) benefitted from adjuvant nivolumab (Opdivo) in terms of improved disease-free survival (DFS) versus placebo, according to results of the phase 3 CheckMate 274 trial (NCT02632409).
Investigators found that nivolumab following surgery conferred a median DFS benefit in both the intent-to-treat (ITT) and PD-L1–positive populations. In the ITT population, DFS in those treated with nivolumab was 21.0 months compared with 10.9 months with placebo (HR, 0.70; 98.31% CI, 0.54-0.89; P < .001).
“This corresponds to a 30% reduction in the risk of disease recurrence or death with nivolumab,” lead author Dean Bajorin, MD, the Frederick R. Adler Senior Faculty Chair at Memorial Sloan Kettering Cancer Center in New York, New York, said during a presentation of the data at the 2021 ASCO Genitourinary Cancers Symposium. “The median DFS is…
